Skip to main content
Whitehawk Therapeutics, Inc. logo

Whitehawk Therapeutics, Inc. — Investor Relations & Filings

Ticker · WHWK ISIN · US00032Q1040 LEI · 549300G3U7TKW1M58L09 US Professional, scientific and technical activities
Open in API
Filings indexed 516 across all filing types
Latest filing 2018-06-22 Director's Dealing
Country US United States of America
Listing US WHWK

About Whitehawk Therapeutics, Inc.

https://ir.whitehawktx.com/

Whitehawk Therapeutics, Inc. is a preclinical-stage oncology company focused on developing advanced antibody-drug conjugate (ADC) therapies. The company applies next-wave platform technologies to established tumor biology to create treatments for difficult-to-treat cancers. Its portfolio features three ADC assets, which are engineered to overcome the limitations of first-generation predecessors through improved tumor targeting and clinical strategies. These assets are in-licensed from WuXi Biologics under an exclusive agreement for global development and commercialization.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2018-06-22 English
424B3 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, which includes a prospectus supplement related to a stock offering and a press release about a clinical study initiation. It is not a full financial report, earnings release, or management discussion. The document primarily serves as a regulatory filing to announce a corporate event and provide related disclosures. It does not contain comprehensive financial statements or detailed financial analysis. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2018-06-11 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content includes a press release about the initiation of dosing in a Phase 1a clinical study, attached as an exhibit. There are no financial statements or detailed financial data presented. The document is short (2759 characters) and primarily serves as an announcement of an event rather than a detailed financial or management report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2018-05-29 English
424B3 Filing
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-Q quarterly report filed pursuant to the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2018. It contains detailed financial statements including balance sheets, statements of operations, cash flows, and notes to the financial statements. It also includes management's discussion and analysis of financial condition and results of operations. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. The presence of unaudited condensed consolidated financial statements and detailed financial data confirms it is an Interim / Quarterly Report.
2018-05-25 English
424B3 Filing
Annual Report Classification · 100% confidence The document is titled 'FORM 10-K' and is described as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934' for the fiscal year ended December 31, 2017. It includes detailed sections typical of an annual report such as Business Overview, Risk Factors, Legal Proceedings, Management's Discussion and Analysis, Financial Statements, and Executive Compensation. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of comprehensive financial and operational information confirms this is the official annual report filing. Therefore, the correct classification is Annual Report (10-K).
2018-05-25 English
424B3 Filing
Investor Presentation Classification · 95% confidence The document is a Form 8-K current report filed by Aerpio Pharmaceuticals, Inc. It includes a corporate presentation intended for investor meetings, as stated in Item 7.01 Regulation FD Disclosure. The presentation focuses on the company's business, clinical data, and strategy, typical of investor presentations. The document is not a full financial report, audit report, or earnings release. It is not an announcement of voting results, management changes, or legal proceedings. The presence of a detailed corporate presentation attached as Exhibit 99.1 and the description of its use in investor meetings clearly identifies this as an Investor Presentation filing. The document length (15,000 characters) and content support this classification with high confidence.
2018-05-25 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.